The use of antithrombotic therapy of any type assumes a thrombotic mechanism for the patient's brain ischemia. Typical, but by no means specific, clinical and radiologic features of atherothrombotic, lacunar and embolic brain ischemia are outlined. The indications for anticoagulant therapy include progressing stroke and cardiogenic brain embolus. According to previous randomized trials, transient ischemic attacks should be managed with aspirin, 1.0 to 1.5 g daily, pending the results of studies of smaller aspirin doses and other plateThis review summarizes the current knowledge and recommendations about antithrombotic therapy in patients with ischemic cerebrovascular disease. The use of anticoagulants or platelet-active agents is based on the assumption that thrombosis within the heart or arterial system is an important substrate of brain ischemia. In some circumstances. brain ischemia occurs by mechanisms that may be only minimally affected by antithrombotic therapy. For example, severely obstructive lesions due to atherosclerosis or inflammatory arteritis might best be managed by surgically removing the flow-limiting plaque or by treating the inflammatory vascular changes rather than by the use of anticoagulant agents or platelet-antiaggregating agents. These examples also illustrate the potential interaction of multiple pathophysiologic mechanisms in the ischemic brain. Thus. the decision to use either anticoagulants or platelet-antiaggregating agents is based on correct identification of the underlying pathophysiology.
let-active drugs. In patients with a suspected cardiogenic brain embolus, anticoagulation should be withheld pending the results of a computed tomographic scan done 24 to 48 hours from onset. If there is no evidence of hemorrhagic transformation or a large area of infarction and the patient does not have sustained hypertension, heparin therapy should be initiated in an effort to prevent a recurrent embolus.
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transient ischemic attack or reversible ischemic neurologic deficit; 2) the vascular territory involved, for example, middle cerebral artery, posteroinferior cerebellar artery or lenticulostriate vessels; and 3) the presumed etiology, for example, atherosclerotic cerebrovascular disease, cardiogenic brain embolism or intracerebral hemorrhage. In approximately 85% of patients presenting with an acute stroke, the cause of the stroke will be ischemia, whereas in 15% the cause will be intracranial hemorrhage (Fig. I ). Of patients with cerebral ischemia, the vast majority (almost 80%) are presumed to have their ischemic stroke as a result of either atherosclerosis of large brain arteries or degenerative occlusion of small arteries. About 15% of patients with ischemic infarction sustain their stroke because of embolism of an intracardiac thrombus. Only about 5% of patients will have a stroke from other causes including arterial dissection, alterations in coagulation, vasculitis or systemic hypotension. Clinical determination of the etiologic basis for stroke in individual patients is occasionally clear, but more often is obscure because of a number of factors, most notably the insensitivity of clinical and laboratory methods and the frequent coexistence of multiple, potentially etiologic factors. Despite careful evaluation, up to 40% of patients with stroke have no definite etiologic basis uncovered (I) .
Clinical determination of etiology. One study (2) found that about 33% of patients with acute stroke had evidence of both a potential cardioembolic source of stroke and atherosclerotic cerebrovascular disease; in half of these patients it was impossible to determine which potentially etiologic factor accounted for their stroke. "Gold standards" for the detennination of the underlying stroke etiology in individual patients do not exist, and decisions must be based on a constellation of the clinical computed tomographic, angiographic, laboratory and cardiac characteristics possessed by the individual patient. Further, the extent to which an occlusive lesion of any origin produces brain ischemia is also dependent on the adequacy of the collateral circulation to the territory supplied by the occluded vessel. Thus, the presence or absence of adequate collateral vessels accounts for the observation that one patient with an internal carotid artery occlusion may have a devastating cerebral hemisphere infarction, whereas another with adequate collateral circulation may sustain only a minor stroke or be totally asymptomatic.
Clinical Characteristics of Atherothrombotic
Brain Ischemia
Atherothrombotic stroke. Atherosclerotic disease of the cervical and large cerebral arteries may produce brain ischemia by means of embolism of plaque material or platelet fibrin thromboemboli (artery to artery emboli) or through the presence of a flow-restricting stenosis that may ultimately lead to thrombus fonnation with occlusion. Certain clinical and radiologic features, while suggestive of an atherothrombotic basis for an ischemic event, are by no means specific. The typical patient with brain infarction secondary to atherothrombotic disease has a history of hypertension, a history of a previous transient ischemic attack (about 50% of cases) and experiences the stuttering onset, at night or on awakening, of a focal neurologic deficit (3) . Carotid bruits are present in 10 to 20%. A computed tomographic scan may show evidence of cortical infarction in the territory supplied by a single cerebral artery. Noninvasive ultrasound studies of the carotid arteries or cerebral angiography may show atherosclerotic plaques of the carotid bifurcation and intracranial vessels. However, these clinical features are not specific. Patients who experience embolism to distal vessels from thrombi originating from cervical atherosclerotic lesions (artery to artery emboli) may have the sudden onset of a maximal neurologic deficit more characteristic of a cardiogenic embolus (4, 5) .
Lacunes. Lacunes ("holes") are 0.2 to 15 mm 3 infarcts of the putamen, thalamus, internal capsule or pons. These cerebral infarcts result from occlusion of the small penetrating vessels arising from the anterior, middle or posterior cerebral arteries and the basilar artery (6, 7) . Hypertension, present in about 75% of cases, is presumably the major risk factor for the occlusive changes in these small arteries. Thirty to 40% of patients with lacunar infarcts have diabetes mellitus. The occlusive process is not one of cholesterolladen atherosclerosis of the large arteries, but rather of a fibrinoid, lipohyalinotic degeneration. The clinical pattern is one of a gradual or stuttering onset in up to 30% of patients. Occasionally, there is a prior transient ischemic attack. A number of specific "lacunar" syndromes have been described, with the most frequent being pure motor stroke, pure sensory stroke, ataxic hemiparesis and the syndrome of dysarthria/clumsy hand. The usual course is one of good recovery of neurologic function.
Many lacunes demonstrated at autopsy or by computed tomography are unassociated with any corresponding stroke history (6, 7) . When bilateral lacunar strokes occur, pseudobulbar palsy with severe dysarthria can result. Although most small, subcortical strokes visible on computed tomography are lacunar as a result of degenerative penetrating artery disease, there is an important caveat. Large or "giant" lacunes (> 1.5 cm) of subcortical structures imply occlusion (25) 5 (5) *Three additional patients had a stroke after anticoagulant therapy was discontinued. AC = anticoagulant therapy; Con = control; FlU = follow-up.
of adjacent penetrating arteries, and are often caused by thrombi or emboli occluding the origin of these vessels. Hence, giant lacunar strokes have little pathophysiologic specificity.
Cardiogenic emboli. About 15% of ischemic brain infarcts are caused by cardiogenic emboli (4, (8) (9) (10) (11) . These emboli arise from thrombi formed on the mitral or aortic valve, on the left ventricillar surface or within the left atrium. One-third of patients with an ischemic stroke have evidence of both atherosclerotic cerebrovascular disease and a potential cardioembolic source (2) . This coexistence of potential etiologic factors leads to irreconcilable diagnostic ambiguity in 50% of these patients. This diagnostic dilemma is further heightened by the realization that some transient cardiac arrhythmias such as paroxysmal atrial fibrillation may produce an embolic stroke leaving no clues, as determined by our available diagnostic probes, to their existence.
The clinicalfeatures that suggest a cardiogenic embolism include the sudden onset of maximal neurologic deficit while the patient is awake and active without a history of ante- (12) (13) (14) . A potential cardiac source of embolism should be particularly sought in patients younger than 50 years of age, those with hemorrhagic infarction by computed tomography and those whose angiographic studies demonstrate either vanishing occlusions of the major intracranial arterial trunks or fail to show atherosclerotic arterial changes. Only rarely will echocardiography, Holter electrocardiographic monitoring or angiography demonstrate an occult intracardiac source of embolus in the absence of a strong clinical suspicion of cardiogenic embolism or a suggestion of a cardiac abnormality by physical examination, chest roentgenogram or electrocardiogram (16, 17) . goes Into one branch
Antithrombotic Therapy in Cerebrovascular Disease
Uncertainty abounds regarding the role of anticoagulant and platelet-antiaggregating agents in patients with transient ischemic attacks, completed strokes or progressing strokes. The multiple pathophysiologic mechanisms of ischemic stroke Completed stroke. The term "completed stroke" describes the situation where a focal brain ischemic event has been persistent and stable for longer than 24 hours. Early small randomized trials (19-27) of long-term anticoagulant therapy in patients with completed stroke showed no significant advantage to anticoagulant therapy in the reduction of recurrent stroke and also suggested that the risks of death and bleeding were increased in the anticoagulant-treated groups. Thus, the use of long-term anticoagulant therapy in patients with completed stroke has largely been abandoned except for its use in those patients with cardiogenic emboli. Proponents of short-term (5 to 7 days) heparin therapy for clinically small or moderate size ischemic strokes hope to prevent progressive stroke or stroke recurrence during this high risk period. Although nonrandomized studies (1) suggest this practice to be efficacious in reducing stroke recurrence or progression, randomized trials (28) of the early institution of heparin therapy have failed to show a significant reduction in rate of stroke recurrence or progression.
The effectiveness of platelet-active agents in the secondary prevention ofstroke recurrence after a completed stroke has been examined with conflicting results. Many of the studies of stroke prevention after a transient ischemic attack have, in fact, included sizable numbers of patients with small completed strokes. In one study (29) in which 85% of the patients studied had had a completed stroke, a significant benefit in favor of aspirin therapy was demonstrated.
Another more recent, large randomized trial (30) restricted to patients with completed stroke failed to demonstrate any benefit of aspirin in a dose of 1.5 g daily in the reduction of stroke or death in treated patients. There is currently a randomized clinical trial underway of ticlopidine therapy after completed stroke to determine the effectiveness of this platelet-active agent in reducing the frequency of stroke recurrence.
In summary. the benefits of long-term antithrombotic therapy after a completed stroke remain uncertain. Chronic anticoagulant therapy appears to be associated with too great a risk, and the benefit of aspirin therapy is controversial. Until more studies are available, most patients will be managed with careful attention to risk factors (such as hypertension) and with aspirin, pending the results of studies of other platelet-active agents.
Progressing stroke. The terms "progressing stroke" or . 'stroke in evolution" describe the clinical situation in which a patient's mild to moderate neurologic deficit worsens over hours or a few days as a result of extension of brain infarction. There are multiple potential causes for deterioration in a patient's neurologic deficit, including edema in the area of infarction, metabolic disturbances, hemorrhage into an area of infarction and coexisting infectious or cardiac disorders. About 20% of patients with an acute brain infarction will develop a progressing stroke pattern (28) . Most of these patients will exhibit their progression within the first 48 hours after their stroke, especially those with a carotid distribution infarct. Patients with vertebrobasilar distribution infarction are at least twice as likely to develop a progressive stroke pattern and the period of risk extends to 5 to 7 days after the acute stroke (31) (32) (33) (34) (35) (36) .
Heparin therapy is generally recommended in patients with progressing stroke provided that other causes for deterioration such as hemorrhage have been excluded. This recommendation is based on two small randomized clinical trials which suggest that further progression may be reduced by half in patients on anticoagulant therapy. However, both of the studies antedated modern methodologic standards of clinical trials and involved small numbers of patients. nonblinded end points and incomplete definition of entry and end point criteria. If heparin is effective in improving the outcome of patients with progressing stroke, it has been assumed that it might also prevent the development of progressing stroke when administered early after a mild or moderate brain infarction. However, a recent randomized trial of heparin (28) showed that 18.9% of patients not receiving heparin experienced progression compared with 15.3% of those receiving heparin. These values were not significantly different.
Transient ischemic attack. Anticoagulant therapy. Four randomized prospective studies (19, 20, 37, 38) have examined the efficacy of anticoagulant therapy in patients with transient ischemic attacks. These studies showed no difference between the anticoagulant-treated and untreated patients; however, there was a combined total of only 93 patients in the treated group and 85 in the control group (Table 1) . The occurrence of stroke was about the same in each group, and there was a trend for increased mortality for those patients treated with anticoagulants. This increase in mortality rate in patients receiving anticoagulant therapy ANTITHROMBOTIC THERAPY IN CEREBROVASCULAR DISEASE lACC Vol 8 
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In summary, it has not been clearly established whether anticoagulant therapy effectively reduces stroke risk after a transient ischemic attack. The increased mortality with longterm anticoagulant use in these patients suggests that longterm anticoagulation for transient ischemic attacks should not be used routinely.
Platelet-active agents. Several studies have examined the effectiveness of platelet-active agents including aspirin, sulfinpyrazone and dipyridamole in patients with a transient ischemic attack (Table 2 ). Eight studies (29, (40) (41) (42) (43) (44) (45) (46) compared aspirin with placebo or some other antithrombotic therapy. The two largest of these studies showed a reduction in stroke and death of 31 % (39) and 45% (29) . All of these studies used aspirin in doses of 1,000 to 1,500 mg/day. Studies examining the efficacy of lower doses of aspirin are now underway. In two of the trials (40, 43) , men treated with aspirin experienced a greater reduction in stroke risk than did women. The effectiveness of sulfinpyrazone has been examined in both Canadian and Italian trials (40, 43) with interesting trends noted. In the Canadian trial (40), stroke and death occurred less frequently in the group receiving both aspirin and sulfinpyrazone. In the Italian study (43) , there was a trend in women for sulfinpyrazone to be more beneficial than aspirin. Dipyridamole has been studied alone and in combination with aspirin and has not been shown to produce any benefit in patients with a transient ischemic attack or minor stroke (Table 3) (29, (47) (48) (49) . A large cooperative study is currently in progress comparing aspirin with ticlopidine hydrochloride. In summary, according to previous randomized trials, it is recommended that aspirin in a dose of I to 1.5 g/day be administered to a patient with a transient ischemic attack. Future studies may clarify the issues of smaller doses of aspirin, any sex differences in responsiveness and the usefulness of other platelet-active agents under investigation.
Cardiogenic Brain Embolism
The decision about the use and timing of anticoagulation after cardiogenic embolism is based on the relative benefits of anticoagulation in preventing recurrent embolism versus the risks of increased hemorrhagic complications. The information needed to make such a decision includes the rate and timing of recurrent embolism, the risks of hemorrhage with anticoagulant use and the nature of any subgroups at particularly increased risk for either recurrent embolus or hemorrhage. Cardioembolic strokes are at particular risk of secondary hemorrhage into the infarct, presumably because distal migration of the embolus from its original site of occlusion results in reperfusion of the infarcted tissue (Fig.  2, 3 and 4) .
Risk of recurrence.
Approximately 12% of patients with cardiogenic brain embolism will experience a recurrence within 2 weeks of their embolic stroke. This rate of recurrence is based on some 15 studies (12, (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) with rates of recurrence that range from 2 to 22% (Table 4 ). The risk of early recurrent emboli appears to be similar in most major cardiac causes of brain embolism including atrial fibrillation, ischemic heart disease and rheumatic heart disease. Two retrospective studies (56, 62) reported lower rates of Immediate heparin administration appears to reduce the rate of recurrent embolism to about one-third that in patients not receiving anticoagulants (55, (58) (59) (60) (61) (62) (63) . The single randomized trial (55) included only 45 patients and demonstrated a lower recurrence rate in patients receiving anticoagulants (Fig. 5) .
Risk of brain hemorrhage. Fear of a symptomatic brain hemorrhage is the major deterrent to immediate anticoagulant therapy in patients with cardiogenic brain embolus. There is a paucity of well designed clinical studies addressing the issue of the risk of brain hemorrhage in these patients. Several studies (12, 55, 59, 60, 64, 65) with an aggregate of 162 patients receiving immediate anticoagulant therapy reported no hemorrhagic worsening. Other studies (58, 61, 63, 66) reported hemorrhagic worsening in from 1.4 to 16% of patients given immediate anticoagulant therapy. This variability in the risk of brain hemorrhage suggests there may be subpopulations of patients at greater or lesser risk for anticoagulation-induced brain hemorrhage.
Hemorrhagic infarction. Hemorrhagic infarction occurs in from 5 to 15% of patients with cardiogenic brain embolism independent of their anticoagulant therapy (12, 13, 67) . Hemorrhagic infarction occurs when there is extravasation of blood into an area of brain infarction such that the blood and ischemic brain tissue occupy the region of infarction. The presumed mechanism of hemorrhagic infarction formation is occlusion of a brain artery, producing ischemic damage to the brain and vascular endothelium followed by reestablishment of blood flow (Fig. 2, 3 and  4 ). Blood then seeps through damaged vascular endothelium, producing varying degrees of hemorrhagic infarction, from small amounts of microscopic hemorrhage invisible to the computed tomographic scan to larger quantities of blood visible as mottled areas of increased density on computed tomography or as large confluent collections of hematoma within an infarct causing a mass effect and clinical worsening. There seems little doubt that these latter large and often lethal brain hemorrhages are overrepresented in the published studies by virtue of the fact that these patients are studied more extensively and are more apt to die, thus becoming part of an autopsy series. In a series (68) of 62 cases of hemorrhagic infarction, 45 had no evidence of clinical worsening in association with the development of hemorrhagic infarction. Seventeen (27%) of the 62 patients had clinical worsening in conjunction with the development of brain hemorrhage as determined by computed tomography. These patients had a variety of underlying cardiac disorders, suggesting no predisposition of certain cardiac abnormalities to their production of hemorrhagic infarction. Large cerebral infarcts occurred in about 60% of patients who developed brain hemorrhage with clinical worsening and in only about 20% of the patients without hemorrhagic worsening. Thus, it would appear that one of the major determinants of the development of hemorrhagic infarction is the size of brain infarction. Large infarcts are more likely to undergo hemorrhagic transformation with or without anticoagulants. If a patient is receiving anticoagulant therapy when the infarct undergoes hemorrhagic transformation, he or she is more likely to experience clinically significant brain hemorrhage than asymptomatic hemorrhagic transformation (13, 58, 69, 70) .
Hemorrhagic infarction does not occur immediately, but awaits the lysis of the embolus and reperfusion of the ischemic brain. Thus, a computed tomographic scan obtained immediately after a brain embolus rarely shows evidence of hemorrhagic infarction, whereas a scan done several days after the embolic stroke shows hemorrhagic infarction in up to 15% of these patients. An analysis of the timing of hemorrhagic infarction suggests that most but not all hemorrhagic infarctions occur within the first 48 hours after an embolic stroke. The therapeutic implication of this observation is that computed tomography performed in the first 12 hours after an embolic stroke cannot effectively exclude the majority of patients who are likely to undergo hemorrhagic transformation. On the other hand, computed tomography done 36 to 48 hours after an embolic stroke will identify the majority of patients who are destined to undergo hemorrhagic transformation. In the series (68) of 62 cases, the group of patients with symptomatic brain hemorrhage not only did have a higher frequency of large infarcts, but also a larger number of them underwent immediate heparin therapy based on a nonhemorrhagic computed tomographic scan obtained within the first 12 hours. Excessive anticoagulation was a poor predictor of the risk of brain hemorrhage with clinical worsening in these patients.
Anticoagulant Therapy in Cardiogenic Brain Embolism
Certain management recommendations can be made based on the assumption that a group of patients at increased risk for brain hemorrhage after an embolic stroke can be identified. This group includes those with large infarcts and those destined to develop hemorrhagic infarction within the first 48 hours. A patient with a suspected cardiogenic brain embolus should not receive immediate anticoagulant therapy. Computed tomography should be done between 24 and 48 hours from onset, and if the patient is found to have a hemorrhagic infarct or a large infarct, anticoagulation should be delayed for 7 to 10 days (Fig. 6 ) Anticoagulation should also be delayed in patients with sustained elevations in blood pressure (that is, > 1801100 mm Hg). Patients with a small or medium-sized infarct, no evidence of hemorrhage by computed tomography and no sustained hypertension should receive heparin. It is hoped that this course of management will provide anticoagulant protection against recurrent embolism in the majority of patients with a recent cardiogenic embolus without subjecting the group at increased risk of hemorrhagic infarction to the additional risk of anticoagulant therapy.
